Exploring WRN Inhibition in MSI Tumors to Expand Synthetic Lethality Strategies Beyond PARP

• See how the MD Anderson Cancer Center are advancing first-in-human trial data for WRN inhibitors in MSI solid tumors
• Interpreting translational relevance and biomarker integration
• Positioning WRN as a synthetic lethality target beyond PARP

Speakers:

Timothy Yap

Professor

The University of Texas MD Anderson Cancer Center